Santacruzamate A Alleviates Pain and Pain-Related Adverse Emotions Through the Inhibition of Microglial Activation in the Anterior Cingulate Cortex

Yan Qin,Qingqing Liu,Saiying Wang,Qinhui Wang,Yaya Du,Jingyue Yao,Yue Chen,Qi Yang,Yumei Wu,Shuibing Liu,Minggao Zhao,Gaofei Wei,Le Yang
DOI: https://doi.org/10.1021/acsptsci.3c00282
IF: 6
2024-01-01
ACS Pharmacology & Translational Science
Abstract:Chronic pain is a complex disease. It seriously affects patients' quality of life and imposes a significant economic burden on society. Santacruzamate A (SCA) is a natural product isolated from marine cyanobacteria in Panama. In this study, we first demonstrated that SCA could alleviate chronic inflammatory pain, pain-related anxiety, and depression emotions induced by complete Freund's adjuvant in mice while inhibiting microglial activation in the anterior cingulate cortex. Moreover, SCA treatment attenuated lipopolysaccharide (LPS)-induced inflammatory response by downregulating interleukin 1β and 6 (IL-1β and IL-6) and tumor necrosis factor-α (TNF-α) levels in BV2 cells. Furthermore, we found that SCA could bind to soluble epoxide hydrolase (sEH) through molecular docking technology, and the thermal stability of sEH was enhanced after binding of SCA to the sEH protein. Meanwhile, we identified that SCA could reduce the sEH enzyme activity and inhibit sEH protein overexpression in the LPS stimulation model. The results indicated that SCA could alleviate the development of inflammation by inhibiting the enzyme activity and expression of sEH to further reduce chronic inflammatory pain. Our study suggested that SCA could be a potential drug for treating chronic inflammatory pain.
What problem does this paper attempt to address?